Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Mountain States] => https://www.survivornet.com/glioma-mountain-states/
[Southeast] => https://www.survivornet.com/southeast/
) )
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Summary View Full Description Full Description The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage III epithelial ovarian cancer who are eligible for primary cytoreductive surgery with no residual disease, or residual disease up to 2.5 mm.
View Eligibility Criteria Eligibility Criteria Inclusion Criteria: candidate for primary CRS histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer Exclusion Criteria: history of previous malignancies within 5 years prior to inclusion FIGO stage IV disease complete primary cytoreduction is impossible prior treatment for the current malignancy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
City of Hope Duarte California, 91010, United States
More Info
MSKCC New York New York New York, 10065, United States
More Info
Rigshospitalet Copenhagen Copenhagen , , Denmark
More Info
CHU de Besancon Besançon , , France
More Info
Institut Bergonié Bordeaux , , France
More Info
o Institut Bergonié, Bordeaux Bordeaux , , France
More Info
Centre Leon Berard, Lyon Lyon , , France
More Info
Institut du Cancer Montpellier Montpellier , , France
More Info
Institut de Cancerologie de l'Ouest, ICO Nantes) Nantes , , France
More Info
Institut Curie Paris Paris , , France
More Info
CHRU Strasbourg Strasbourg , , France
More Info
Oncopole, Institute Universitaire du Cancer de Toulouse (IUCT Toulouse) Toulouse , , France
More Info
Mater Misericordiae University Hospital, Dublin Dublin , , Ireland
More Info
Policlinico Sant'Orsola, Bologna Bologna , , Italy
More Info
Fondazione Policlinico A Gemelli IRCCS Roma , , Italy
More Info
Antoni van leeuwenhoek Amsterdam Noord-Holland, 1066C, Netherlands
More Info
Amsterdam UMC Amsterdam , , Netherlands
Catharina Hospital Eindhoven , , Netherlands
Medisch Spectrum Twente Enschede , , Netherlands
UMCG Groningen , , Netherlands
Leiden University Medical Center (LUMC) Leiden , , Netherlands
Maastricht UMC+ Maastricht , , Netherlands
Radboud MC Nijmegen , , Netherlands
Erasmus MC Rotterdam , , Netherlands
Alice Bjoernlund-Larsen Uppsala , , Sweden
More Info How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up